---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-013082"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2022-05-19T23:59:59+00:00"
generated_at: "2026-06-25T09:08:28.624468+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# DiaMedica shareholders approve 2M share increase in 2019 omnibus incentive plan and new director compensation cap

## Summary
- Shareholders approved amendment to 2019 Omnibus Incentive Plan, increasing authorized shares by 2,000,000.
- The amended plan imposes a dollar limit on non-employee director compensation per calendar year.
- All six director nominees were elected; Richard Pilnik received 3.4M for, 1.3M withheld.
- Baker Tilly US, LLP appointed as independent registered public accounting firm for 2022.
- The plan became effective May 18, 2022 and expires on May 21, 2029.

## SEC filing metadata
- accession: 0001437749-22-013082
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2022-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774922013082/0001437749-22-013082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774922013082/dmtp20220518_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-013082
- JSON: https://secwatch.observer/filing/0001437749-22-013082.json
- Plain text: https://secwatch.observer/filing/0001437749-22-013082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.